Equity Overview
Price & Market Data
Price: $0.64
Daily Change: -$0.0794 / 12.40%
Range: $0.62 - $0.75
Market Cap: $1,558,665
Volume: 57,740
Performance Metrics
1 Week: 8.23%
1 Month: -14.51%
3 Months: -71.60%
6 Months: -62.99%
1 Year: -81.72%
YTD: -60.18%
Company Details
Employees: 2
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.